Daniel Getts, Ph.D., Founder and CEO
Oct. 10 | 1:30pm | Rentschler ATMP Ballroom
Cambridge, MA
(Private)
Myeloid Therapeutics is a clinical-stage, immune-cell programming company, focused on new treatment options for patients with solid tumors. The Company designs and deploys its proprietary mRNA-coded CARs for in vivo programming of immune cells.
The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.
October 7-9, 2024
Arizona Biltmore
Phoenix, AZ
